Xilio Therapeutics (XLO) Operating Leases (2020 - 2026)
Xilio Therapeutics (XLO) posted Operating Leases of $5.3 million for Q1 2026, down 6.36% sequentially from $5.6 million in Q4 2025, and down 20.85% YoY from $6.6 million in Q1 2025.
Xilio Therapeutics (XLO) Operating Leases (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Operating Leases for 7 years, with the latest figure at $5.3 million in Q1 2026.
- Quarterly Operating Leases fell 20.85% year-over-year to $5.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (down 20.85% YoY) and the FY2025 annual result came in at $5.6 million, down 19.31% from the prior year.
- Operating Leases fell to $5.3 million in Q1 2026 per XLO's latest filing, from $5.6 million in the prior quarter.
- Over five years, Operating Leases peaked at $9.9 million in Q1 2022 and troughed at $5.3 million in Q1 2026.
- A 5-year average of $7.8 million and a median of $7.9 million in 2024 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2026: Operating Leases declined 8.6% in 2022, then slipped 20.85% in 2026.
- Over 5 years, Operating Leases stood at $9.2 million in 2022, then decreased by 11.39% to $8.1 million in 2023, then declined by 14.59% to $7.0 million in 2024, then retreated by 19.31% to $5.6 million in 2025, then declined by 6.36% to $5.3 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $5.3 million, $5.6 million, and $6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Xilio Therapeutics | 178.33 Mn | 42.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.88 Mn |
| Mar 31, 2026 | 5.25 Mn |
| Dec 31, 2025 | 5.61 Mn |
| Sep 30, 2025 | 5.96 Mn |
| Jun 30, 2025 | 6.30 Mn |
| Mar 31, 2025 | 6.64 Mn |
| Dec 31, 2024 | 6.95 Mn |
| Sep 30, 2024 | 7.26 Mn |
| Jun 30, 2024 | 7.57 Mn |
| Mar 31, 2024 | 7.86 Mn |
| Dec 31, 2023 | 8.14 Mn |
| Sep 30, 2023 | 8.42 Mn |
| Jun 30, 2023 | 8.68 Mn |
| Mar 31, 2023 | 8.95 Mn |
| Dec 31, 2022 | 9.19 Mn |
| Sep 30, 2022 | 9.43 Mn |
| Jun 30, 2022 | 9.66 Mn |
| Mar 31, 2022 | 9.89 Mn |
| Dec 31, 2021 | 10.11 Mn |
| Sep 30, 2021 | 10.32 Mn |